Table 7.
Baseline characteristics of patients (Clinic HCC). Data are presented as n (%).
| Characteristics | Levels | High expression of MMP1 | Low expression of MMP1 | p value* |
|---|---|---|---|---|
| N = 54 | N = 54 | |||
| Age (no. (%)) | > 60 | 19 (35.2%) | 25 (46.3%) | 0.327 |
| ≤ 60 | 35 (64.8%) | 29 (53.7%) | ||
| Gender (no. (%)) | Female | 6 (11.1%) | 6 (11.1%) | 1.000 |
| Male | 48 (88.9%) | 48 (88.9%) | ||
| T stage (no. (%)) | T1 | 19 (35.2%) | 28 (51.9%) | 0.224 |
| T2 | 15 (27.8%) | 15 (27.8%) | ||
| T3 | 13 (24.1%) | 8 (14.8%) | ||
| T4 | 7 (13%) | 3 (5.6%) | ||
| N stage (no. (%)) | N0 | 45 (83.3%) | 47 (87%) | 0.786 |
| N1 | 9 (16.7%) | 7 (13%) | ||
| M stage (no. (%)) | M0 | 52 (96.3%) | 54 (100%) | 0.495 |
| M1 | 2 (3.7%) | 0 (0%) | ||
| Pathologic stage (no. (%)) | Stage I | 16 (29.6%) | 27 (50%) | 0.019 |
| Stage II | 8 (14.8%) | 13 (24.1%) | ||
| Stage III | 19 (35.2%) | 8 (14.8%) | ||
| Stage IV | 11 (20.4%) | 6 (11.1%) | ||
| Tumor status (no. (%)) | tumor free | 36 (66.7%) | 42 (77.8%) | 0.283 |
| with tumor | 18 (33.3%) | 12 (22.2%) | ||
| Residual tumor (no. (%)) | R0 | 41 (75.9%) | 47 (87%) | 0.376 |
| R1 | 4 (7.4%) | 2 (3.7%) | ||
| R2 | 9 (16.7%) | 5 (9.3%) | ||
| Histologic grade (no. (%)) | G1 | 7 (14.6%) | 11 (21.2%) | 0.145 |
| G2 | 16 (33.3%) | 24 (46.2%) | ||
| G3&4 | 25 (52.1%) | 17 (32.7%) | ||
| AFP(ng/ml) (no. (%)) | > 400 | 36 (66.7%) | 23 (42.6%) | 0.020 |
| ≤ 400 | 18 (33.3%) | 31 (57.4%) | ||
| Albumin(g/dl) (no. (%)) | < 3.5 | 19 (35.2%) | 8 (14.8%) | 0.026 |
| ≥ 3.5 | 35 (64.8%) | 46 (85.2%) | ||
| Child–Pugh grade (no. (%)) | A | 33 (61.1%) | 48 (88.9%) | 0.002 |
| B | 21 (38.9%) | 6 (11.1%) | ||
| Vascular invasion (no. (%)) | No | 28 (53.8%) | 35 (66%) | 0.282 |
| Yes | 24 (46.2%) | 18 (34%) |
*Compared with each group (Fisher exact test, or Pearson’s chi-square test). p value < 0.05 was considered statistically significant (highlighted in bold).